Thrivent Financial for Lutherans
ACOR

Thrivent Financial for Lutherans’s Acorda Therapeutics ACOR Stock Holding History

Thrivent Financial for Lutherans’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-335
Closed -$38K – 2312
2020
Q1 		$38K Buy
335
+16
+5% +$3.15K ﹤0.01% 2247
2019
Q4 		$78K Buy
319
+1
+0.3% +$252 ﹤0.01% 2203
2019
Q3 		$110K Buy
318
+60
+23% +$32.6K ﹤0.01% 2175
2019
Q2 		$238K Buy
258
+7
+3% +$8.6K ﹤0.01% 2096
2019
Q1 		$401K Buy
251
+22
+10% +$39.6K ﹤0.01% 1896
2018
Q4 		$428K Buy
229
+5
+2% +$10.9K ﹤0.01% 1659
2018
Q3 		$528K Sell
224
-45
-17% -$139K ﹤0.01% 1660
2018
Q2 		$927K Sell
269
-73
-21% -$224K ﹤0.01% 1302
2018
Q1 		$969K Buy
342
+99
+41% +$296K ﹤0.01% 1252
2017
Q4 		$625K Buy
243
+5
+2% +$14.2K ﹤0.01% 1539
2017
Q3 		$675K Buy
238
+4
+2% +$10.5K ﹤0.01% 1395
2017
Q2 		$554K Buy
234
+18
+8% +$35.7K ﹤0.01% 1461
2017
Q1 		$544K Buy
216
+10
+5% +$28.8K ﹤0.01% 1482
2016
Q4 		$466K Buy
206
+10
+5% +$23.8K ﹤0.01% 1532
2016
Q3 		$491K Buy
196
+9
+5% +$26.9K ﹤0.01% 1458
2016
Q2 		$572K Sell
187
-1,512
-89% -$4.92M ﹤0.01% 1358
2016
Q1 		$5.39M Sell
1,699
-12,154
-88% -$50.5M 0.03% 558
2015
Q4 		$71.1M Buy
13,853
+247
+2% +$1.08M 0.34% 70
2015
Q3 		$43.3M Buy
13,606
+4,247
+45% +$16.5M 0.23% 112
2015
Q2 		$37.4M Buy
9,359
+859
+10% +$3.32M 0.21% 121
2015
Q1 		$33.9M Buy
8,500
+131
+2% +$600K 0.19% 137
2014
Q4 		$41M Buy
8,369
+729
+10% +$3.13M 0.23% 111
2014
Q3 		$31.1M Buy
7,640
+212
+3% +$795K 0.18% 135
2014
Q2 		$30M Buy
7,428
+2
+0% +$8.15K 0.17% 140
2014
Q1 		$33.8M Buy
7,426
+2,330
+46% +$9.42M 0.21% 111
2013
Q4 		$17.9M Buy
5,096
+811
+19% +$3.16M 0.11% 207
2013
Q3 		$17.6M Buy
4,285
+4,162
+3,384% +$17.9M 0.11% 203
2013
Q2 		$488 Buy
+123
New +$506K ﹤0.01% 937

Other funds holding ACOR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Thrivent Financial for Lutherans's ACOR Position: Q2 2020 in Review

Thrivent Financial for Lutherans sold out of Acorda Therapeutics (ACOR) in Q2 2020, closing a stake of 335 shares — an estimated $38K sold.

Thrivent Financial for Lutherans first reported a position in ACOR in Q2 2013 and held it in 28 quarters. The position peaked at $71.1M in Q4 2015. 79 funds tracked by Wall St. Rank hold ACOR as of Q2 2020.

  • Thrivent Financial for Lutherans reported no remaining Acorda Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 335 Acorda Therapeutics shares in Q2 2020, an estimated $38K.
  • Thrivent Financial for Lutherans first reported a position in Acorda Therapeutics in Q2 2013 and held it in 28 quarters.
  • Thrivent Financial for Lutherans's Acorda Therapeutics position peaked at $71.1M in Q4 2015.
  • 79 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2020.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2020, filed 12 Aug 2020.